Bromian(V) potasu – frakcja wdychana : dokumentacja proponowanych dopuszczalnych wielkości narażenia zawodowego

Starek, A.

doi:10.5604/01.3001.0012.0753

Artykuł - szczegóły

Tytuł artykułu

Bromian(V) potasu – frakcja wdychana : dokumentacja proponowanych dopuszczalnych wielkości narażenia zawodowego

Autorzy

Starek A.

Treść / Zawartość

Pełne teksty:

Pobierz

Identyfikatory

DOI

10.5604/01.3001.0012.0753

Warianty tytułu

Języki publikacji

Abstrakty

Potassium bromate – inhalable fraction : documentation of proposed values of occupational exposure limits (OELs)

Słowa kluczowe

bromian(V) potasu nefrotoksyczność genotoksyczność NDS

potassium bromate (V) nephrotoxicity genotoxicity MAC value

Wydawca

Centralny Instytut Ochrony Pracy - Państwowy Instytut Badawczy

Czasopismo

Podstawy i Metody Oceny Środowiska Pracy

Rocznik

2018

Tom

Nr 2 (96)

Strony

35--59

Opis fizyczny

Bibliogr. 95 poz., tab.

Twórcy

autor

Starek A.

mfstarek@cyf-kr.edu.pl

Collegium Medicum Uniwersytetu Jagiellońskiego 30-688 Kraków ul. Medyczna 9

Bibliografia

1. ACGIH (2015). Guide to Occupational Exposure Values. Ahmad M.K., Khan A.A., Mahmood R. (2012a). Alterations in brush border membrane enzymes, carbohydrate metabolism and oxidative damage to rats intestine by potassium bromate. Biochimie 94, 2776–2782.
2. Ahmad M.K., Naqshbandi A., Fareed M., Mahmood R. (2012b). Oral administration of a nephrotoxic dose of potassium bromate, a food additive, alters renal redox and metabolic status and inhibits brush border membrane enzymes in rats. Food Chemistry 134, 980–985.
3. Ahmad M.K., Khan A.A., Mahmood R. (2013). Taurine ameliorates potassium bromate-induced kidney damage in rats. Amino Acids 45, 1109–1121.
4. Ahmad M.K., Mahmood R. (2012). Oral administration of potassium bromate, a major water disinfection by-product, induces oxidative stress and impairs the antioxidant power of rat blood. Chemosphere 87, 750–756.
5. Arashidani K., Iwamoto-Tanaka N., Muraoka M., Kasai K. (1998). Genotoxicity of ribo- and deoxyribonucleosides of 8-hydroxyguanine, 5-hydroxycytosine, and 2-hydroksyadenine: induction of SCE in human lymphocytes and mutagenicity in Salmonella typhimurium TA100. Mutat. Res. 403, 223–227.
6. Awogi T., Murata K., Uejima M., Kuwahara T., Asanami S., Shimono K., Morita T. (1992). Induction of micronucleated reticulocytes by potassium bromate and potassium chromate in CD-1 male mice. Mutat. Res. 278, 181–185.
7. Ballmaier D., Epe B. (1995). Oxidative DNA damage induced by potassium bromate under cell free conditions and in mammalian cells. Carcinogenesis 16, 335–342.
8. Ballmaier D., Epe B. (2006). DNA damage by bromate: Mechanism and consequences. Toxicology 221, 166–171.
9. Campbell K.C. (2006). Toxicology. Bromate-induced ototoxicology. Toxicology 221, 205–211.
10. Centralny Rejestr Danych o Narażeniu na Substancje Chemiczne, ich Mieszaniny, Czynniki lub Procesy Technologiczne o Działaniu Rakotwórczym lub Mutagennym (2015). Łódź, IMP.
11. Cheng K.C., Cahill D.S., Kasai H., Nishimura S., Loeb L.A. (1992). 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J. Biol. Chem. 267, 166–172.
12. Chipman J.K., Davies J.E., Parsons J.L., Nair J., O'Neill G., Fawell J.K. (1998). DNA oxidation by potassium br
13. Cho D.H., Hong J.T., Chin K., Cho T.S., Lee B.M. (1993). Organotropic formation and disappearance of 8-hydroxydeoxyguanosine in the kidney of Sprague- -Dawley rats exposed to adriamycin and KBrO3. Cancer Lett. 74, 141–145.
14. CIR (2006). Potassium Bromate. [W:] Ingredients found safe, with qualifications. Cosmetic Ingredient Review [http://www.cirsafety.org/staff_files/safewithqualifications. pdf].
15. Crosby L.M. (2000). Studies on Mechanisms of Potassium Bromate-Induced Mesothelial Carcinogenesis in the Male F344 Rat. A thesis for the Degree of Ph.D. U.S. North Carolina State University.
16. Crosby L.M., Hyder K.S., DeAngelo A.B., Kepler T.B., Gaskill B., Benavides G.R., Yoon L., Morgan K.T. (2000). Morphologic analysis correlates with gene expression changes in cultured F344 rat mesothelial cells. Toxicol. Appl. Pharmacol. 169, 205–221.
17. DeAngelo A.B., George M.H., Kilburn S.R., Moore T.M., Wolf D.C. (1998). Carcinogenicity of potassium bromate administered in the drinking water to male B6C3F1 mice and F3444/N rats. Toxicol. Pathol. 26(5), 587–594.
18. Delker D., Hatch G., Allen J., Crissman B., George M., Geter D., Kilburn S., Moore T., Nelson G., Roop B., Slade R., Swank A., Ward W., DeAngelo A. (2006). Molecular biomarkers of oxidative stress associated with bromate carcinogenicity. Toxicology 221, 158–165.
19. Dodd D.E., Layko D.K., Cantwell K.E., Willson G.A., Thomas R.S. (2013). Subchronic toxicity evaluation of potassium bromate in Fischer 344 rats. Environ. Toxicol. Pharmacol. 36, 1227–1234.
20. Durrant P.J., Durrant B. (1965). Zarys współczesnej chemii nieorganicznej. Warszawa, PWN, 1058.
21. EPA (2001). Toxicological Review of Bromate. In Support of Summary Information on the Integrated Risk Information System (IRIS). Washington DC, U.S. Environmental Protection Agency.
22. Expert Committee on Food Additives (1964). Seventh Report on the Specifications for the Identity and Purity of Food Additives and Their Toxicological Evaluation: Emulsifiers, Stabilizers, Bleaching and Maturing Agents. World Health Organization Technical Report, Series 281, Geneva [cyt. za: Kurokawa i in. 1990].
23. Farombi E.O., Alabi M.C., Akuru T.O. (2002). Kolaviron modulates cellular redox status and impairment of membrane protein activities induced by potassium bromate (KBrO3) in rats. Pharmacol. Res. 45(1), 63–68.
24. FDA (2006). Food Additive Status List. Center for Food Safety and Applied Nutrition. Food and Drug Administration. Washington DC [http://www.cfsan.fda.gov/~dms/opaappa. html].
25. Fisher N., Hutchinson J.B., Berry R., Hardy J., Ginocchio A.V., Waite V. (1979). Long-term toxicity and carcinogenicity studies of the bread improver potassium bromate. 1. Studies in rats. Food. Cosmet. Toxicol. 17, 33–39.
26. Fujie K., Shimazu H., Matsuda M., Sugiyama T. (1988). Acute cytogenetic effects of potassium bromate on rat bone marrow cells in vivo. Mutat. Res. 206, 455–458.
27. Fujii M., Oikawa K., Saito H., Fukuhara C., Onosaka S., Tanaka T. (1984). Metabolism of potassium bromate in rats. I. In vivo studies. Chemosphere 13, 1207–1212.
28. Ginocchio A.V., Waite V., Hardy J., Fisher N., Hutchinson J.B., Berry R. (1979). Long-term toxicity and carcinogenicity studies of the bread improver potassium bromate. 2. Studies in mice. Food Cosmet. Toxicol. 17, 41–47.
29. Giri U., Iqbal M., Athar M. (1999). Potassium bromate (KBrO3) induces renal proliferative response and damage by elaborating oxidative stress. Cancer Res. 135, 181–188.
30. Gradus D., Rhoads M., Bergstrom L.B. Jordan S.C. (1984). Acute bromate poisoning associated with renal failure and deafness presenting as hemolytic uremic syndrome. Am. J. Nephrol. 4, 188–191.
31. Hayashi M., Sofuni T., Ishidate M. Jr. (1982). High- -sensitivity in micronucleus induction of a mouse strain (MS). Mutat. Res. 105, 253–256.
32. IARC (1999). IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 73. Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances. Lyon, 481–496.
33. ICSC (2003). International Chemical Safety Cards. Potassium Bromate.
34. Informacje toksykologiczne Europejskiej Agencji ds. Chemikaliów [http://echa.europa.eu/registration-dossier/ -/registered-dossier/13209].
35. Ishidate M. Jr., Sofuni T., Yoshikawa K., Hayashi M., Nohmi T., Sawada M., Matsuoka A. (1984). Primary mutagenicity screening of food additiver currently used in Japan. Food Chem. Toxicol. 22, 623–636 [cyt. za: Kurokawa i in. 1990].
36. Kasai H., Nishimura S., Kurokawa Y., Hayashi Y. (1987). Oral administration of the renal carcinogen, potassium bromate, specifically produces 8-hydroxydeoxyguanosine in rat target organ. Carcinogenesis 12, 1959–1961.
37. Kawachi T., Yahagi T., Kada T., Tazima Y., Ishidate M. Jr., Sasaki M., Sugiyama T. (1980). Cooperative programme on short-term assays for carcinogenicity in Japan. [W:] Molecular and Cellular Aspects of Carcinogen Screening Tests. IARC Scientific Publications No. 27. [Red.] R. Montesano, H. Bartsch, L. Tomatis. International Agency for Research on Cancer. France, Lyon, 330–333 [cyt. za: Kurokawa i in. 1990].
38. Kawana K., Nakaoka T., Horiguchi Y., Watanabe S., Kawauchi S. (1991). Toxicological study of potassium bromate. I. Absorption, metabolism and excretion of potassium bromate after oral administration in rats. Eisei Kaguku 37(4), 258–265 [cyt. za: PHG 2009].
39. Kawanishi S., Murata M. (2006). Mechanism of DNA damage induced by bromate differs from general types of oxidative stress. Toxicology 221, 172–178.
40. Khan N., Sharma S., Alam A., Saleem M., Sultana S. (2001). Tephrosia purpurea ameliorates N-diethylnitrosamine and potassium bromate-mediated renal oxidative stress and toxicity in Wistar rats. Pharmacol. Toxicol. 88, 294– 299.
41. Khan N., Sharma S., Sultana S. (2003). Nigella sativa (black cumin) ameliorates potassium bromate-induced early events of carcinogenesis: diminution of oxidative stress. Hum. Exp. Toxicol. 22, 193–203.
42. Khan N., Sharma S., Sultana S. (2004). Attenuation of potassium bromate-induced nephrotoxicity by coumarin (1,2-benzopyrone) in Wistar rats: chemoprevention against free radical-mediated renal oxidative stress and tumor promotion response. Redox Rep. 9(1), 19–28.
43. Khan N., Sultana S. (2004). Abrogation of potassium bromate-induced renal oxidative stress and subsequent cell proliferation response by soy isoflavones in Wistar rats. Toxicology 201, 173–184.
44. Kitto W., Dumars K.W. (1949). Potassium bromate poisoning. J. Pediatr. 35(2), 197–200.
45. Knappenberger R.C. (1952). Potassium bromate poisoning. J. Pediatr. 40(1), 105–108.
46. Kurata Y., Diwan B.A., Ward J.M. (1992). Lack of renal tumor-initiating activity of a single dose of potassium bromate, a genotoxic renal carcinogen in male Fischer 344/Ncr rats. Fd. Chem. Toxicol. 30(3), 251–259.
47. Kurokawa Y., Aoki S., Imazawa T., Hayashi Y., Matsushima Y., Takamura N. (1985). Dose-related enhancing effect of potassium bromate on renal tumorigenesis in rats initiated with N-ethyl-N-hydroxyethylnitrosamine. Jpn. J. Cancer Res. (Gann) 76, 583–589 [cyt. za: Kurokawa i in. 1990].
48. Kurokawa Y., Aoki S., Matsushima Y., Takamura N., Imazawa T., Hayashi Y. (1986a). Dose-response studies on the carcinogenicity of potassium bromate in F344 rats after long-term oral administration. J. Natl. Cancer Inst. 77, 977–982.
49. Kurokawa Y., Takayama S., Konishi Y., Hiasa Y., Asahina S., Takahashi M., Maekawa A., Hayashi Y. (1986b). Long-term in vivo carcinogenicity test of potassium bromate, sodium hypochlorite and sodium chlorite conducted in Japan. Environ. Health Persp. 69, 221–235.
50. Kurokawa Y., Hayashi Y., Maekawa A., Takahashi M., Kokubo T. (1982). Induction of renal cell tumors in F-344 rats by oral administration of potassium bromate, a food additive. Gann 73, 335–338 [cyt. za: Kurokawa i in. 1990].
51. Kurokawa Y., Maekawa A., Takahashi M., Hayashi Y. (1990). Toxicity and carcinogenicity of potassiumApplied Nutrition. Food and Drug Administration. Washington DC [http://www.cfsan.fda.gov/~dms/opaappa. html]. bromate – a new renal carcinogen. Environ. Health Persp. 87, 309–335.
52. Kurokawa Y., Takahashi M., Kokubo T., Ohno Y., Hayashi Y. (1983). Enhancement by potassium bromate of renal tumorigenesis initiated by N-ethyl-N-hydroxyethylnitrosamine in F-344 rats. Gann 74, 607–610 [cyt. za: Kurokawa i in. 1990].
53. Kurokawa Y., Takamura N., Matsuoka C., Imazawa T., Matsushima Y., Onodera H., Hayashi Y. (1987). Comparative studies on lipid peroxidation in the kidney of rats, mice and hamsters and on the effect of cysteine, glutathione and diethyl maleate treatment on mortality and nephrotoxicity after administration of potassium bromate. J. Am. Coll. Toxicol. 6, 489–501.
54. Lee Y.-S., Choi J.-Y., Park M.-K., Choi E.-M., Kasai H., Chung M.-H. (1996). Induction of OH8Gua glycosylase in rat kidneys by potassium bromate (KBrO3), a renal oxidative carcinogen. Mutat. Res. 364, 227–233.
55. Le Page F., Margot A., Grollman A.P., Sarasin A., Gentil A. (1995). Mutagenicity of a unique 8-oxoguanine in a human Ha-ras sequence in mammalian cells. Carcinogenesis 16, 2779–2784.
56. Levin D.E., Hollstein M.C., Christman M.F., Schwiers E.A., Ames B.N. (1982). A new Salmonella tester strain (TA102) with A:T base pairs at the site of mutation detects oxidative mutagens. Proc. Natl. Acad. Sci. USA 79, 7445– 7449 [cyt. za: Kurokawa i in. 1990].
57. List of MAK and BAT Values (2014). Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area Report 50. Deutsche Forschungsgemeinschaft authorized and signed by Professor Dr. Andrea Hartwig Chair of the Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area. Bonn, Weinheim, WILEY-VCH Verlag GmbH & Co. KGaA [http://onlinelibrary.wiley.com/ doi/10.1002/ 9783527682027.oth2/pdf].
58. Luan Y., Suzuki T., Palanisamy R., Takashima Y., Sakamoto H., Sakuraba M., Koizumi T., Saito M., Matsufuji H., Yamagata K., Yamaguchi T., Hayashi M., Honma M. (2007). Potassium bromate treatment predominantly causes large deletions, but not GC > TA transversion in human cells. Mutat. Res. 619, 113–123.
59. Matsumoto I. (1973). Clinical and experimental studies on the ototoxicity of bromate. Otol. Fukuoka 19, 220–236 [cyt. za: Kurokawa i in. 1990].
60. Matsushima Y., Takamura N., Imazawa T., Kurokawa Y., Hayashi Y. (1986). Lack of carcinogenicity of potassium bromate after subcutaneous injection to newborn mice and newborn rats. Sci. Rep., Tohoku Univ. Ser.-C 33, 22–26 [cyt. za: Kurokawa i in. 1990].
61. McDorman K.S., Pachkowski B.F., Nakamura J., Wolf D.C., Swenberg J.A. (2005). Oxidative DNA damage from potassium bromate exposure in Long-Evans rats is not enhanced by a mixture of drinking water disinfection by-products. Chem.-Biol. Interact. 152, 107–117.
62. Murata M., Bansho Y., Inoue S., Ito K., Ohnishi S., Midorikawa K., Kawanashi S. (2001). Requirement of glutathione and cysteine in guanine-specific oxidation of DNA by carcinogenic potassium bromate. Chem. Res. Toxicol. 14, 678–685.
63. Nakajima M., Kitazawa M., Oba K., Kitagawa Y., Toyoda Y. (1989). Effect of route of administration in the micronucleus test with potassium bromate. Mutat. Res. 223, 399– 402.
64. National Toxicology Program Final Report (1996). Sodium Bromate: Short Term Reproductive and Developmental Toxicology Study When Administered to Sprague-Dawley Rats in the Drinking Water (NTP/NIEHS No. NOI-ES-15323; NTP-RDGT No. 94-007). Research Triangle Park, NC [cyt. za: EPA 2001].
65. Nishioka H., Fujii H., Sun B., Aruoma O.I. (2006). Comparative efficacy of oligonol, catechin and (-)-epigallocatechin 3-O-gallate in modulating the potassium bromate-induced renal toxicity in rats. Toxicology 226, 181–187.
66. Okada E., Fujiishi Y., Narumi K., Kado S., Wako Y., Kawasako K., Kaneko K., Ohyama W. (2015). Evaluation of repeated dose micronucleus assays of the liver and gastrointestinal tract using potassium bromate: a report of the collaborative study by CSGMT/JEMS.MMS. Mutat. Res. 780-781, 94–99.
67. Parsons J.L., Chipman J.K. (2000). The role of glutathione in DNA damage by potassium bromate in vitro. Mutagenesis 15, 311–316.
68. Patnaik P. (1992). A Comprehensive Guide to the Hazardous Properties of Chemical Substances. New York, Von Nostrand Reinhold [cyt. za: Crosby 2000].
69. Patty's Toxicology (2001). 5 ed., vol. 3. New York, J. Wiley and Sons, Inc, 806–808.
70. Pazera T., Rzemieniuk T. (2000) Browarnictwo. Warszawa, WSiP.
71. PHG, Public Health Goals (2009). Public Health Goals for Chemicals in Drinking Water. Bromate. Governor of the State of California, California Environmental Protection Agency, Office of Environmental Health Hazard Assessment.
72. Richter H., Vamvakas S. (1998). S-(1,2-Dichlorovinych)- -L-cysteine-induced dedifferentiation and p53 gene mutations in LLC-PK1 cells: a comparative investigation with S-(2-chloroethyl)cysteine, potassium bromate, cis-platinum and styrene oxide. Toxicol. Lett. 94, 145– 157.
73. Rozporządzenie Ministra Pracy i Polityki Społecznej z dnia 6 czerwca 2014 r. w sprawie najwyższych dopuszczalnych stężeń i natężeń czynników szkodliwych dla zdrowia w środowisku pracy. DzU 2014, poz. 817.
74. Rozporządzenie Ministra Zdrowia z dnia 30 marca 2005 r. w sprawie list substancji niedozwolonych lub dozwolonych z ograniczeniami do stosowania w kosmetykach oraz znaków graficznych umieszczanych na opakowaniach kosmetyków. DzU 2005, nr 72, poz. 642.
75. Rozporządzenie Ministra Zdrowia z dnia 22 listopada 2010 r. w sprawie dozwolonych substancji dodatkowych. DzU 2010, nr 232, poz. 1525.
76. Rozporządzenie Ministra Zdrowia z dnia 24 lipca 2012 r. w sprawie substancji chemicznych, ich mieszanin, czynników lub procesów technologicznych o działaniu rakotwórczym lub mutagennym w środowisku pracy. DzU 2012, poz. 890 ze zm. z 2015 r. poz. 1090.
77. Rozporządzenie Ministra Zdrowia z dnia 13 listopada 2015 r. w sprawie jakości wody przeznaczonej do spożycia przez ludzi. DzU 2015, poz. 1989.
78. Rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 z dnia 16.12.2008 r. w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin, zmieniające i uchylające dyrektywy 67/648/EWG i 1999/45/WE oraz zmieniające rozporządzenie WE nr 1907/2006 (tzw. rozporządzenie CLP). Dz. Urz. UE L 353 z dnia 31.12.2008 r. z późn. zm. 79. Rozporządzenie REACH (WE) nr 1907/2006 Parlamentu Europejskiego i Rady z dnia 18 grudnia 2006 r. w sprawie rejestracji, oceny, udzielania zezwoleń i stosowanych ograniczeń w zakresie chemikaliów (REACH), utworzenia Europejskiej Agencji Chemikaliów, zmieniające dyrektywę 1999/45/WE oraz uchylające rozporządzenie Rady (EWG) nr 793/93 i rozporządzenie Komisji (WE) nr 1488/94, jak również dyrektywę Rady 76/769/EWG i dyrektywy Komisji 91/155/EWG, 93/67/EWG, 93/105/WE i 2000/21/WE [w wersji sprostowanej]. Dz. Urz. UE L 136 z dnia 29.05.2007 r. z późn. zm., s. 3.
79. RTECS (2016). [komputerowa baza danych].
80. Saad H.B., Nasri I., Elwej A., Krayem N., Jarraya R., Kallel C., Zeghal N., Amara I.B. (2014). A mineral and antioxidant-rich extract from the red marine algae Alsidium corallinum exhibits cytoprotective effects against potassium bromate-induced erythrocyte oxidative damages in mice. Biol. Trace Elem. Res. 160, 85–96.
81. Sai K., Hayashi M., Takagi A., Hasegawa R., Sofuni T., Kurokawa Y. (1992). Effects of antioxidants on induction of micronuclei in rat peripheral blood reticulocytes by potassium bromate. Mutat. Res. 269, 113–118.
82. Suzuki T., Hayashi M., Hakura A., Asita O.A., Kodama Y., Honma M. (1995). Combination effects of clastogens in the mouse peripheral blood micronucleus assay. Mutagenesis 10, 31–36.
83. The Merck Index (2006). An Encyclopedia of Chemicals, Drugs, and Biologicals. [Red.] M.J. O'Neil. 14 ed., Merck & Co., Inc. Whitehouse Station, NJ, USA, 1315.
84. Takamura N., Kurokawa Y., Matsushima Y., Imazawa T., Onodera H., Hayashi Y. (1985). Long-term oral administration of potassium bromate in male Syrian golden hamsters. Sci. Rep. Res. Inst. Tohoku Univ. Ser. C 32, 43–46 [cyt. za: Kurokawa i in. 1990].
85. Tanaka K., Oikawa K., Fukuhara C., Saito H., Onosaka S., Min K.S., Fujii M. (1984). Metabolism of potassium bromate in rats. II. In vitro studies. Chemosphere 13, 1213–1219.
86. The Ministry of Health and Welfare Japan (1986). The Japanese Standards of Food Additives. 5th Edition, Tokyo, 433.
87. Umemura T., Kitamura Y., Kanki K., Maruyama S., Okazaki K., Imazawa T., Nishimura T., Hasegawa R., Nishikawa A., Hirose M. (2004). Dose-related changes of oxidative stress and cell proliferation in kidneys of male and female F344 rats exposed to potassium bromate. Cancer Sci. 95(5), 393–398.
88. Umemura T., Kurokawa Y. (2006). Etiology of bromate- -induced cancer and possible models of action-studies in Japan. Toxicology 221, 154–157.
89. Umemura T., Takagi A., Sai K., Hasegawa R., Kurokawa Y. (1998). Oxidative DNA damage and cell proliferation in kidneys of male and female rats during 13-weeks exposure to potassium bromate (KBrO3). Arch. Toxicol. 72, 264–269.
90. Umemura T., Tasaki M., Kijima A., Okamura T., Inoue T., Ishii Y., Suzuki Y., Masui N., Nohmi T., Nishikawa A. (2009). Possible participation of oxidative stress in causation of cell proliferation and in vivo mutagenicity in kidneys of gpt delta rats treated with potassium bromate. Toxicology 257, 46–52.
91. WHO (1992). Technical Report Series: 828, Thirty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. Geneva, 29–30.
92. Wnuk M., Szymczak W. (2003). Bromian(V) potasu. Wytyczne Szacowania Ryzyka Zdrowotnego dla Czynników Rakotwórczych 17, 57–74.
93. Wolf D.C., Crosby L.M., George M.H., Kilburn S.R., Moore T.M., Miller R.T., DeAngelo A.B. (1998). Time- and dose-dependent development of potassium bromate-induced tumors in male Fischer 344 rats. Toxicol. Pathol. 26(6), 724–729.
94. Wolfe G.W., Kaiser L.B., Lanning L., Chapin R.E., Klinefelter G., Hunter E.S. (1996). Short term reproductive and development effects of sodium bromate in S-D rats when administered in the drinking water (Abstract). Toxicologist 30, 121–122 [cyt. za: EPA 2001].
95. Yamaguchi T., Wei M., Hagihara N., Omori M., Wanibuchi H., Fukushima S. (2008). Lack of mutagenic and toxic effects of low dose potassium bromate on kidneys in the Big Blue rat. Mutat. Res. 652, 1–11.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-657074db-c926-4f26-8f32-303d91d6bb84